Cost-utility analysis of botulinum toxin type A versus oral drug treatment in patients with severe blepharospasm in Thailand
Among patients with severe blepharospasm, both onaBoNT-A and aboBoNT-A were considered a cost-effective strategy under the Thai willingness to pay threshold of 4,613 USD/QALY. Having aboBoNT-A was slightly more favorable due to lower cost, using a conversion ratio of 1U of onaBoNT-A: 3U of aboBoNT-A.
Authors
- Sureerat Ngamkiatphaisan
- Unchalee Permsuwan (ORCID: https://orcid.org/0000-0002-6909-2789)
- Parima Hirunwiwatkul (ORCID: https://orcid.org/0000-0002-7599-1991)
- Jiruth Sriratanaban (ORCID: https://orcid.org/0000-0001-5456-1717)
- Niphon Chirapapaisan (ORCID: https://orcid.org/0000-0002-4321-0142)
Institutions
- Thai Red Cross Society (TH)
- Siriraj Hospital (TH)
- Chulalongkorn University (TH)
- Mahidol University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Chiang Mai University (TH)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1371/journal.pone.0319926
- Citations
- 1
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39